Ser12
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser12  -  PPAR-alpha (human)

Site Information
EsPLCPLsPLEAGDL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1789802

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 1 , 2 ) , phospho-antibody ( 2 )
Disease tissue studied:
liver cancer ( 1 , 2 )
Relevant cell line - cell type - tissue:
hepatocyte-liver ( 2 ) , HepG2 (hepatic) ( 1 , 2 )

Upstream Regulation
Putative upstream phosphatases:
PPP1CA (human) ( 2 ) , PPP2CA (human) ( 2 )
Treatments:
nafenopin ( 2 ) , okadaic_acid ( 2 ) , pirinixic acid ( 2 ) , prasterone ( 2 )

Downstream Regulation
Effects of modification on biological processes:
transcription, inhibited ( 1 , 2 )

References 

1

Oh KJ, et al. (2011) Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism. Am J Physiol Endocrinol Metab 300, E624-32
21224484   Curated Info

2

Tamasi V, et al. (2008) Modulation of receptor phosphorylation contributes to activation of peroxisome proliferator activated receptor alpha by dehydroepiandrosterone and other peroxisome proliferators. Mol Pharmacol 73, 968-76
18079279   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.